Targeting ASIC1 in primary progressive multiple sclerosis: evidence of neuroprotection with amiloride.

Targeting ASIC1 in primary progressive multiple sclerosis: evidence of neuroprotection with amiloride.

Show other versions (1)

Neurodegeneration is the main cause for permanent disability in multiple sclerosis. The effect of current immunomodulatory treatments on neurodegeneration is insufficient. Therefore, direct neuroprotection and myeloprotection remain an important therapeutic goal. Targeting acid-sensing ion channel 1...

Full description

Bibliographic Details
Main Authors: Arun, T, Tomassini, V, Sbardella, E, de Ruiter, M, Matthews, L, Leite, M, Gelineau-Morel, R, Cavey, A, Vergo, S, Craner, M, Fugger, L, Rovira, A, Jenkinson, M, Palace, J
Format: Journal article
Language:English
Published: 2013

Similar Items

Similar Items